A study of venetoclax and azacitidine before stem cell transplant for MDS
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs (venetoclax and azacitidine) given before a stem cell transplant to see if it improves outcomes for people with a certain type of myelodysplastic syndromes (MDS) that is higher risk. If you have higher-risk MDS and are planning a stem cell transplant, this may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed MDS (a bone marrow disorder) with at least 10% abnormal cells in the bone marrow.
- You are 18 years or older.
- Your MDS is classified as higher risk with a score above 4.5 on a standard test (IPSS-R).
- You have good enough organ function, like a heart pumping ability of at least 50%, normal liver enzymes, and good kidney function.
- You have an ECOG performance status of 0 to 2 (meaning you are fully active or up and about more than 50% of the time).
- You are planning to receive a stem cell transplant from a donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
This study tests a combination of venetoclax (a targeted drug) with a mini stem cell transplant (called a microtransplant) using a partially matched donor. It is for people with higher-risk MDS who cannot have a standard transplant.
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
This trial tests whether adding a drug called venetoclax to a standard transplant preparation regimen (called treosulfan-based reduced intensity conditioning) can improve the success of a stem cell transplant for patients with certain blood cancers like AML, MDS/AML, or high-risk MDS. The goal is to see if this combination makes the transplant safer and more effective.
This trial studies a combination of two medicines (venetoclax and azacitidine) as a bridge to a stem cell transplant for people with a hard-to-treat type of AML (like secondary AML or with low bone marrow cells). The goal is to get the leukemia under control so a transplant can be done successfully.
Hear when a new Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.